What is CF PharmTech?
CF PharmTech operates as a specialized pharmaceutical enterprise focused on the integrated management of respiratory conditions, including asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. The company distinguishes itself through a comprehensive R&D pipeline that encompasses aerosol sprays, dry powder inhalers, and nasal sprays. By bridging the gap between clinical necessity and pharmaceutical innovation, CF PharmTech provides high-quality, accessible inhalation therapies. Their market position is defined by a commitment to addressing significant unmet clinical needs, positioning them as a critical provider in the global respiratory health sector.
How much funding has CF PharmTech raised?
CF PharmTech has raised a total of $205M across 3 funding rounds:
Series D
$65M
Series E
$90M
Series F
$50M
Series D (2017): $65M, investors not publicly disclosed
Series E (2020): $90M led by CMB International, GTJA Investment, Oriza Holdings, New Alliance Capital, Everest Venture Capital, GT Capital, Xiangcheng Financial Holdings, Co-stone Asset Management, Longmen Venture Capital, CR-CP Life Science Fund, and Finnova Capital
Series F (2020): $50M, investors not publicly disclosed
Key Investors in CF PharmTech
New Alliance Capital
New Alliance Capital is a Shanghai-based investment firm specializing in venture capital and private equity, focusing on high-growth potential within the Chinese healthcare and technology sectors.
Oriza Holdings
Oriza Holdings is a prominent investment group that manages a diverse portfolio of funds, with a strong emphasis on life sciences, biotechnology, and innovative pharmaceutical development.
Everest Venture Capital
Everest Venture Capital is a specialized investment firm that provides strategic backing to early and growth-stage companies, particularly those operating within the life sciences and medical technology industries.
What's next for CF PharmTech?
With the recent influx of capital, CF PharmTech is well-positioned to accelerate its clinical trial programs and expand its manufacturing capabilities for its diverse inhalation portfolio. The strategic focus will likely shift toward international market penetration and the optimization of its supply chain to meet the rising prevalence of chronic respiratory diseases. As the company matures, the emphasis on regulatory approval for its pipeline candidates will be paramount to maintaining its competitive edge. Investors are closely monitoring the firm's ability to translate its research-heavy model into sustained commercial success within the highly regulated global pharmaceutical market.
See full CF PharmTech company page
